Maravai LifeSciences (MRVI) IPO Opens 18% Higher

Today's IPO for Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) open for trading at $31.95 after pricing its upsized initial public offering of 60,000,000 shares of Class A common stock at a public offering price of $27.00 per share.

Additionally, Maravai has granted the underwriters a 30-day option to purchase up to an additional 9,000,000 shares of Class A common stock at the initial public offering price, less underwriting discounts and commissions.

Morgan Stanley, Jefferies and Goldman Sachs & Co. LLC are acting as joint book-running managers for the offering. BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel and KeyBanc Capital Markets are also acting as joint book-running managers, and Academy Securities, Loop Capital Markets, Penserra Securities LLC and Tigress Financial Partners are acting as co-managers for the offering.

Perella Weinberg Partners L.P. served as capital markets advisor to Maravai. Kirkland & Ellis LLP provided legal counsel to Maravai and Davis Polk & Wardwell LLP provided legal counsel to the underwriters.

Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases through its portfolio of companies and their proprietary capabilities and products. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis, bioprocess impurity detection and analysis, and protein labeling and detection to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.

You May Also Be Interested In

• Nscale targets up to $3B in US IPO as soon as September - Bloomberg
• Andersen prices secondary offering of 4.28M shares at $44 each
• BofA Securities Starts Mobility Global (MBGL) at Neutral